Trial Profile

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Mar 2025 According to a Vir Biotechnology media release, this study is a part of the company's registrational program named ECLIPSE, which is comprised of 2 Phase 3 studies (ECLIPSE 1 and ECLIPSE 2) and one phase 2b study (ECLIPSE 3). ECLIPSE program is designed to enable regulatory submissions to multiple regulatory agencies and to support reimbursement and access.
13 Mar 2025 According to a Vir Biotechnology media release, first patient has been enrolled in this study.
13 Mar 2025 According to a Vir Biotechnology media release, status changed from planning to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com